The head of artificial intelligence and machine learning at GSK believes the advanced technologies are on course to make drug research and development the most productive in the group’s 307-year history.
The newly focused FTSE 100 pharmaceuticals group is seeking to revive its pipeline after lengthy criticism of its productivity and its share price.
GSK has made the technologies one of three priorities, alongside focusing on the immune system and human genetics. The drugs group spun-off Haleon, its consumer healthcare business, as a separate FTSE 100 company on the London Stock Exchange in July in a big strategic overhaul by Dame Emma Walmsley, the group chief executive, designed to generate billions of pounds of firepower to invest in its core pharmaceutical and vaccines pipeline.
Using
